Here's the decision logic: If your current or target dose is 2.5 mg: Choose 10 mg/mL (25 units) or 5 mg/mL (50 units)
It's a multi-agonist peptide, targeting not just one but three receptors: GLP-1, GIP, and glucagon
Tirzepatide carries the typical gastrointestinal (GI) risks associated with GLP-1 receptor agonists: Nausea, vomiting, diarrhea, and digestive disturbances (particularly during dose escalation)
Think of it as prepping your body to do its job efficiently, setting the stage for the best possible results from your treatment
It is important to recognise that tiredness can arise from multiple factors, including the underlying condition being treated (type 2 diabetes itself), changes in eating patterns due to reduced appetite, gastrointestinal side effects affecting nutrition, or concurrent medications